Parametrica Management Ltd bought a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) in the 1st quarter, HoldingsChannel.com reports. The fund bought 1,079 shares of the medical research company’s stock, valued at approximately $330,000.
Several other institutional investors have also made changes to their positions in BIO. Levin Capital Strategies L.P. grew its stake in Bio-Rad Laboratories by 7,126.2% in the fourth quarter. Levin Capital Strategies L.P. now owns 569,205 shares of the medical research company’s stock worth $132,181,000 after purchasing an additional 561,328 shares in the last quarter. Tower House Partners LLP acquired a new position in Bio-Rad Laboratories in the fourth quarter worth about $52,249,000. Norges Bank acquired a new position in Bio-Rad Laboratories in the fourth quarter worth about $46,327,000. First Trust Advisors LP grew its stake in Bio-Rad Laboratories by 82.2% in the fourth quarter. First Trust Advisors LP now owns 186,624 shares of the medical research company’s stock worth $43,338,000 after purchasing an additional 84,187 shares in the last quarter. Finally, Intermede Investment Partners Ltd acquired a new position in Bio-Rad Laboratories in the fourth quarter worth about $18,902,000. Institutional investors own 64.30% of the company’s stock.
Shares of NYSE BIO opened at $298.01 on Friday. The company has a current ratio of 4.57, a quick ratio of 3.24 and a debt-to-equity ratio of 0.13. Bio-Rad Laboratories, Inc. has a 52-week low of $220.05 and a 52-week high of $345.15. The stock has a market capitalization of $8.77 billion, a price-to-earnings ratio of 51.03, a price-to-earnings-growth ratio of 2.74 and a beta of 1.23.
Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Wednesday, May 8th. The medical research company reported $1.65 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.12 by $0.53. Bio-Rad Laboratories had a net margin of 24.84% and a return on equity of 4.15%. The firm had revenue of $553.98 million for the quarter, compared to analysts’ expectations of $548.82 million. As a group, analysts anticipate that Bio-Rad Laboratories, Inc. will post 7.15 EPS for the current fiscal year.
In other Bio-Rad Laboratories news, EVP Timothy S. Ernst sold 345 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $290.00, for a total value of $100,050.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 27.84% of the company’s stock.
A number of research firms recently commented on BIO. Barclays lifted their price target on Bio-Rad Laboratories from $315.00 to $340.00 and gave the stock an “overweight” rating in a research note on Friday, March 1st. Deutsche Bank lifted their price target on Bio-Rad Laboratories from $330.00 to $350.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Zacks Investment Research upgraded Bio-Rad Laboratories from a “hold” rating to a “strong-buy” rating and set a $360.00 price target for the company in a research note on Wednesday, March 6th. Finally, ValuEngine upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, May 9th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $365.00.
ILLEGAL ACTIVITY WARNING: This news story was reported by Stock Observer and is the property of of Stock Observer. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.thestockobserver.com/2019/05/17/parametrica-management-ltd-buys-shares-of-1079-bio-rad-laboratories-inc-bio.html.
Bio-Rad Laboratories Profile
Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.
Read More: Why are gap-down stocks important?
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.